SLSylvain Loric

Sylvain Loric

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sylvain Loric has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First evidence of subclinical renal tubular injury during sickle-cell crisis

    by Vincent Audard, Stéphane Moutereau, Gaetana Vandemelebrouck, Anoosha Habibi, Mehdi Khellaf, Philippe Grimbert, Yves Levy, Sylvain Loric, Bertrand Renaud, Philippe Lang, et al.

    The pathophysiologic mechanisms classically involved in sickle-cell nephropathy include endothelial dysfunction and vascular occlusion. Arguments demonstrating that ischemia-reperfusion injury-related kidney damage might coincide with vaso-occlusive crisis (VOC) are lacking.


  • 074: Potential role of peptide natriuretic and troponin-T to predict cardiac echocardiographic findings in hereditary transthyretin amyloidosis patients

    by Thibaud Damy, Jean-François Deux, Stéphane Moutereau, Soulef Guendouz, Dania Mohti, Stéphane Rappeneau, Sylvain Loric, Jean-Pascal Lefaucheur, Luc Hittinger, Violaine Planté-Bordeneuve

  • Open Access

    Androgens regulate Hedgehog signalling and proliferation in androgen‐dependent prostate cells

    by Nanor Sirab, Stéphane Terry, Frank Giton, Josselin Caradec, Mihelaiti Chimingqi, Stéphane Moutereau, Francis Vacherot, Alexandre de la Taille, Jean‐Claude Kouyoumdjian, Sylvain Loric

    Prostate cancer (PCa) is androgen sensitive in its development and progression to metastatic disease. Hedgehog (Hh) pathway activation is important in the initiation and growth of various carcinomas including PCa. We and others have observed aberrations of Hh pathway during the progression of PCa to the castration-resistant state. The involvement of androgen signalling in Hh pathway activation, however, remains largely elusive. Here we investigate the direct role of androgen signalling on Hh pathway. We examined the effect of Dihydrosterone (DHT), antiandrogen, bicalutamide, and Hh pathway inhibitor, KAAD-cyclopamine in four human prostate cell lines (two cancerous: LNCaP, VCaP, and two normal: PNT2 and PNT2-ARm which harbours a mutant version of androgen receptor (AR) that is commonly found in LNCaP). Cell proliferation as well as Hh pathway members (SHH, IHH, DHH, GLI, PTCH) mRNA expression levels were assessed. We showed that KAAD-cyclopamine decreased cell proliferation of DHT-stimulated LNCaP, VCaP and PNT2-ARm cells. SHH expression was found to be downregulated by DHT in all AR posititve cells. The negative effect of DHT on SHH expression was counteracted when cells were treated by bicalutamide. Importantly, KAAD-cyclopamine treatment seemed to inhibit AR activity. Moreover, bicalutamide as well as KAAD-cyclopamine treatments induced GLI and PTCH expression in VCaP and PNT2-ARm. Our results suggest that Hh pathway activity can be regulated by androgen signalling. Specifically, we show that the DHT-induced inhibition of Hh pathway is AR dependent. The mutual interaction between these two pathways might be important in the regulation of cell proliferation in PCa.


  • A bias in quantitative RT-PCR limit of detection is induced by the use of cancer cell lines in the molecular detection of circulating tumor cells

    by Justine Prost À la Denise, Anne-France Dekairelle, Cédric Desbene, Stéphane Moutereau, Richard Douard, Michel Devanlay, Pascal Eschwege, Jean-Luc Gala, Sylvain Loric

    Article A bias in quantitative RT-PCR limit of detection is induced by the use of cancer cell lines in the molecular detection of circulating tumor cells was published on June 1, 2011 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 49, issue 6).

  • Improved neopterin ELISA kit: a good compromise between HPLC results and clinical practice

    by Stéphane Moutereau, Najia Ech Chad, Michel Devanlay, Liliane Esmilaire, Sylvain Loric


  • Open Access

    Is GAPDH a relevant housekeeping gene for normalisation in colorectal cancer experiments?

    by J Caradec, N Sirab, D Revaud, C Keumeugni, S Loric


  • Open Access

    Reply: 18S is an appropriate housekeeping gene for in vitro hypoxia experiments

    by J Caradec, N Sirab, C Keumeugni, D Revaud, S Loric


  • Open Access

    ‘Desperate house genes’: the dramatic example of hypoxia

    by J Caradec, N Sirab, C Keumeugni, S Moutereau, M Chimingqi, C Matar, D Revaud, M Bah, P Manivet, M Conti, et al.

    Microenvironmental conditions in normal or tumour tissues and cell lines may interfere on further biological analysis. To evaluate transcript variations carefully, it is common to use stable housekeeping genes (HKG) to normalise quantitative microarrays or real-time polymerase chain reaction results. However, recent studies argue that HKG fluctuate according to tissues and treatments. So, as an example of HKG variation under an array of conditions that are common in the cancer field, we evaluate whether hypoxia could have an impact on HKG expression. Expression of 10 commonly used HKG was measured on four cell lines treated with four oxygen concentrations (from 1 to 20%). Large variations of HKG transcripts were observed in hypoxic conditions and differ along with the cell line and the oxygen concentration. To elect the most stable HKG, we compared the three statistical means based either on PCR cycle threshold coefficient of variation calculation or two specifically dedicated software. Nevertheless, the best HKG dramatically differs according to the statistical method used. Moreover, using, as a reference, absolute quantification of a target gene (here the proteinase activating receptor gene 1 (PAR1) gene), we show that the conclusions raised about PAR1 variation in hypoxia can totally diverge according to the selected HKG used for normalisation. The choice of a valid HKG will determine the relevance of the results that will be further interpreted, and so it should be seriously considered. The results of our study confirm unambiguously that HKG variations must be precisely and systematically determined before any experiment for each situation, to obtain reliable normalised results in the experimental setting that has been designed. Indeed, such assay design, functional for all in vitro systems, should be carefully evaluated before any extension to other experimental models including in vivo ones.


  • Open Access

    Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study

    by P Eschwège, S Moutereau, S Droupy, R Douard, J-L Gala, G Benoit, M Conti, P Manivet, S Loric

    In clinically organ-confined prostate cancer patients, bloodstream tumour cell dissemination generally occurs, and may be enhanced by surgical prostate manipulation. To evaluate cancer-cell seeding impact upon patient recurrence-free survival, 155 patients were prospectively enrolled then followed. Here, 57 patients presented blood prostate cell shedding preoperatively and intraoperatively (group I). Of the 98 preoperatively negative patients, 53 (54%) remained negative (group II) and 45 (46%) became intraoperatively positive (group III). Median biological and clinical recurrence-free time was far shorter in group I (36.2 months, Pvs 65.0). Such 5-year follow-up data show that preoperative circulating prostate cells are an independent prognosis factor of recurrence. Moreover, tumour handling induces cancer-cell seeding but surgical blood dissemination does not accelerate cancer evolution.


  • Should kidney tubular markers be adjusted for urine creatinine? The example of urinary cystatin C

    by Marc Conti, Stéphane Moutereau, Liliane Esmilaire, Cédric Desbene, Karim Lallali, Michel Devanlay, Antoine Durrbach, Philippe Manivet, Pascal Eschwège, Sylvain Loric

    Evaluation of specific urinary markers with respect to urine creatinine (uCreat) is common. However, as uCreat is a function of both glomerular filtration and tubular secretion, using uCreat for specific tubular markers, suggests that glomerular function is normal, and there is no tubular secretion. Thus, adjusting values of any tubular marker to uCreat, especially in patients with acute or even moderate chronic renal failure, can be misleading. Using urine cystatin-C (uCST3) as a model tubular marker for following 120 kidney graft recipients daily, we evaluated the utility of either uCST3 alone or the uCST3/uCreat ratio to detect tubular damage. All positive kidney biopsies were always associated with a uCST3>0.18 mg/L. Using the uCST3/uCreat ratio, discrepancies regarding biopsy status were observed in nine patients (4 false positive, 5 false negative results). In two patients, variability of uCreat appeared to be the most important factor causing inconsistent uCST3/uCreat ratios. With a negative predictive value (NPV) of 85.7%, uCST3/uCreat can lead to errors in clinical interpretation. These errors can be avoided when estimates of tubular damage are based on uCST3 concentrations alone (NPV=100%). We recommend using the uCST3 value to evaluate the extent of renal tubular damage. Indeed, our conflicting results on uCST3/uCreat can be extended to every marker of tubular function. Evaluating a urine marker specific for renal tubular damage to a second urine marker that is itself strongly dependent upon glomerular or other renal or non-renal conditions, impairs its clinical relevance and may lead to incorrect interpretations. Correction with uCreat can be performed only in pure glomerulopathy, when specific markers of glomerular function are measured (i.e., urinary albumin). In all other cases of renal diseases, such correction is inappropriate and should be avoided. Clin Chem Lab Med 2009;47:1553-6.